Abstract |
The activity of CDP-840, a novel, selective phosphodiesterase IV inhibitor was determined in a leukotriene-dependent non-human primate model of allergic asthma. Measurements of specific airway resistance (sRaw) were recorded in a dual chamber plethysmograph for 1 h and 3-5 h after challenge of allergic conscious squirrel monkeys with an aerosol of ascaris antigen. Orally administered CDP-840 (10 mg/kg; 1 h before challenge) produced partial inhibition (41 and 45%, respectively) of both the acute (1 h post antigen) response and the late (3-5 h post antigen) response to antigen but failed to alter the response to an aerosol of leukotriene D4. In a second series of experiments, intravenous CDP-840 (5 mg/kg; 30 min before challenge) showed improved potency, producing 82% inhibition of the early and 51% inhibition of the late phase response. CDP-840 was inactive when tested intravenously at 1 mg/kg and was inactive against the 3-5 h response when administered after the early phase response (5 mg/kg; i.v. 60 min post antigen challenge). The novel phosphodiesterase IV inhibitor CDP-840 selectively inhibited antigen-induced bronchoconstriction in conscious squirrel monkeys. This effect appears to be independent of any direct bronchodilator action. It is concluded that the activity of CDP-840 in this model may be due to an inhibitory effect on mediator (e.g., leukotriene) release.
|
Authors | T R Jones, M McAuliffe, C S McFarlane, H Piechuta, D Macdonald, I W Rodger |
Journal | Canadian journal of physiology and pharmacology
(Can J Physiol Pharmacol)
Vol. 76
Issue 2
Pg. 210-7
(Feb 1998)
ISSN: 0008-4212 [Print] Canada |
PMID | 9635162
(Publication Type: Journal Article)
|
Chemical References |
- Antigens, Helminth
- Leukotrienes
- Phosphodiesterase Inhibitors
- Pyridines
- CDP 840
- 3',5'-Cyclic-AMP Phosphodiesterases
- Cyclic Nucleotide Phosphodiesterases, Type 4
|
Topics |
- 3',5'-Cyclic-AMP Phosphodiesterases
(antagonists & inhibitors)
- Animals
- Antigens, Helminth
(pharmacology)
- Ascaris
(chemistry)
- Asthma
(chemically induced, prevention & control)
- Bronchoconstriction
(drug effects)
- Cyclic Nucleotide Phosphodiesterases, Type 4
- Leukotrienes
(pharmacology)
- Male
- Phosphodiesterase Inhibitors
(pharmacology)
- Pyridines
(pharmacology)
- Saimiri
- Skin Tests
- Time Factors
|